Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalon GloboCare Corp. (NASDAQ: ALBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents. These filings describe Avalon as a commercial‑stage company focused on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate operations. Through its SEC reports, Avalon details material events such as acquisitions, financing arrangements, Nasdaq listing matters, and progress on its proposed merger with YOOV Group Holding Limited.
In recent Form 8‑K filings, Avalon has reported the acquisition of RPM Interactive, Inc. through its subsidiary Avalon Quantum AI, LLC, adding a generative AI powered SaaS platform for automated short‑form video creation. Other 8‑K and 8‑K/A filings outline senior secured promissory notes, bridge notes, waivers and amendments, unregistered sales of equity securities, and changes to preferred stock designations, including Series C and Series E preferred stock. Filings also document Nasdaq correspondence regarding compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b) and the company’s steps to address those requirements.
SEC filings further describe Avalon’s Agreement and Plan of Merger with YOOV Group Holding Limited and the related Registration Statement on Form S‑4, which contains a preliminary proxy statement/prospectus. These documents explain the structure of the proposed merger, the conditions to closing, and the anticipated focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions following completion. Additional disclosures cover the company’s share issuances, beneficial ownership limitations, and updates on outstanding notes and conversion terms.
On Stock Titan, users can review Avalon’s 8‑K, 8‑K/A, 10‑K, and other SEC filings, while AI‑powered tools help summarize complex sections, highlight key terms, and surface information on topics such as financing, preferred stock features, Nasdaq listing status, and merger‑related disclosures. This makes it easier to understand how Avalon’s precision diagnostics, cellular therapy IP, AI software assets, and capital structure are reflected in its official regulatory record.
Avalon Globocare Corp. reported changes to executive and board compensation. On March 4, 2026, the Board approved a cash bonus of $175,000 for Chief Financial Officer Luisa Ingargiola in recognition of her efforts advancing the business and financial position during the 2025 fiscal year.
The Board also increased annual fees payable to lead director Steven Saunders to $95,000 for his service on the Board of Directors. These actions reflect compensation decisions rather than operational or financial performance metrics.
Avalon GloboCare Corp. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC jointly state beneficial ownership of 490,197 shares of Common Stock, representing 7.0% of the outstanding common stock based on 7,042,348 shares outstanding as of February 27, 2026.
The filing excludes two warrants held by Intracoastal (each exercisable into 490,197 shares) because each warrant is not exercisable until stockholder approval of the issuances and contains a blocker provision limiting exercise to prevent ownership above 4.99%. Without those blocker provisions (and if exercisable), the reporting persons may be deemed to beneficially own 1,470,591 shares.
Avalon GloboCare Corp. is asking stockholders to approve several financing-related actions and a potential reverse stock split at a March 30, 2026 virtual special meeting. Holders of 6,264,740 common shares as of February 17, 2026 can vote.
The Company seeks approval for conversions tied to July 2025 convertible notes, a December 2025 bridge note plus 100,000 commitment shares, and its Series C preferred stock, each needed to comply with Nasdaq Listing Rule 5635(d) because conversions could exceed 20% of prior outstanding shares.
Stockholders are also asked to approve exchanging 5,000 Series D preferred shares held by Chairman Wenzhao Lu for 2,074,689 common shares, issuing 450,000 restricted shares to an advisor, and authorizing a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑25, without reducing authorized common shares, to help maintain Nasdaq listing and potentially broaden investor interest. An adjournment proposal would allow extra time to solicit votes if needed. The Board unanimously recommends voting “FOR” all proposals.
Avalon GloboCare Corp. entered into a private placement with institutional investors, raising approximately $3.25 million gross through the sale of 6,372,550 shares of common stock (or pre-funded warrants in lieu) at $0.51 per share, plus accompanying Series A-1 and Series A-2 warrants.
The company expects net proceeds of about $2.8 million, which it plans to use to repay certain outstanding debt and for working capital and general corporate purposes. The warrants, covering up to 12,745,100 shares, carry a $0.51 exercise price and become exercisable after stockholder approval, with expirations five years and eighteen months from that approval, respectively.
Avalon GloboCare Corp. filed a current report describing that it has been accepted into the AMD AI Developer Program. This gives Avalon access to AMD Developer Cloud credits, advanced tools, training, and community resources aimed at supporting and accelerating artificial intelligence development.
Avalon plans to use these resources mainly through its AI-focused subsidiary Avalon Quantum AI LLC (AQAI) to scale automated commentary video generation, future enterprise documentation tools, and an AI-powered workflow automation platform. Management highlights this as part of Avalon’s broader repositioning as a technology-focused AI company.
Avalon Globocare Corp. entered a financing deal with an accredited investor, issuing a promissory note with a principal amount of
The note can be prepaid at 96–98% of principal plus interest depending on timing, and is scheduled for a
The filing also reports that directors William B. Stilley III, Wilbert J. Tauzin II and Tevi Troy resigned from the board on
Avalon GloboCare Corp. director Michael Mathews reported receiving 1,364.840 shares of the company’s Series E Non-Voting Convertible Preferred Stock at a stated price of $0 per share. These preferred shares were issued in exchange for 2,600,000 common shares of RPM Interactive, Inc. as part of Avalon GloboCare’s acquisition of RPM.
Each share of this Series E preferred stock is perpetual, so it has no expiration date, and it becomes convertible into Avalon GloboCare equity at any time from and after May 12, 2026, or earlier if the company consents in writing.
Avalon GloboCare Corp. director Mathews Michael filed an initial insider ownership report on Form 3. The filing establishes his status as a director of the company but does not list any specific share transactions or changes in ownership.
Avalon Globocare Corp. completed an amended transaction to sell 100% of the membership interests of its subsidiary Avalon RT 9 Properties, LLC, which owns the company’s Freehold, New Jersey office property, to its board chairman Wenzhao Lu.
The amended deal provides total consideration of $9,000,000, consisting of $3,100,000 in cash previously advanced under the original agreement and the satisfaction in full of an approximately $5,900,000 mortgage balance. Following closing, Avalon is released from all obligations as guarantor on that mortgage.
The company also amended a $375,000 unsecured bridge note dated December 11, 2025, extending the first, second, and third payment deadlines to March 16, 2026, April 15, 2026, and May 15, 2026, respectively.
Avalon Globocare Corp. entered into a financing deal with Vanquish Funding Group involving a $233,910 promissory note, sold for $207,000 with a $26,910 original issue discount and a one-time 12% interest charge. The note requires seven monthly payments starting August 15, 2026 and matures on February 15, 2027. If an event of default occurs, the lender can demand 150% of the default amount and the note becomes convertible into common stock at 75% of the lowest trading price over the prior ten trading days, subject to a 19.99% issuance cap. Avalon plans to use the proceeds for general working capital and paid a $10,000 fee to Digital Offering LLC. The company also issued 300,000 common shares to consultants for services rendered, receiving no cash proceeds.